66 citations
,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
1 citations
,
May 1992 in “Pharmacological Research”
6 citations
,
January 2024 in “ACS Medicinal Chemistry Letters” Cepharanthine and berbamine may affect SK channels, influencing their therapeutic effects.
18 citations
,
May 2024 in “Pharmaceutics” Improved delivery systems can enhance oleanolic acid's effectiveness in treating various conditions.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
1 citations
,
October 2024 in “JAAD Case Reports” Baricitinib effectively treated hair loss and inflammation in a patient with alopecia areata and lichen planopilaris.
25 citations
,
July 2022 in “Pharmaceutics” Spanlastic nanovesicles can improve efinaconazole delivery through nails.
3 citations
,
January 2021 in “Therapeutic advances in infectious disease” A 9-year-old girl with a healthy immune system was successfully treated for a severe fungal scalp infection caused by Microsporum audouinii.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” CD101 is highly effective in treating dermatophytosis in guinea pigs.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
January 2026 in “Dermatology and Therapy”
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
February 2010 in “Journal of The American Academy of Dermatology” Posaconazole is a promising new treatment for toenail fungus.
Baricitinib effectively regrows hair in severe alopecia areata cases.
75 citations
,
January 1997 in “Journal of ethnopharmacology” Santolina chamaecyparissus oil effectively fights fungal infections.
37 citations
,
January 2016 in “Drug design, development and therapy” Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
138 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
Baricitinib may effectively treat oral lichen planus.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
13 citations
,
September 2022 in “International Journal of Molecular Sciences” Five existing drugs may help fight Swine Acute Diarrhea Syndrome Coronavirus.
October 2024 in “International Journal For Multidisciplinary Research” Wedelolactone may help treat chronic diseases due to its strong antioxidant properties.
4 citations
,
December 2022 in “Evidence-based Complementary and Alternative Medicine” Phenolic compounds from Quercus acutissima leaves, especially casuarinin, may help treat acne.
1 citations
,
January 2012 in “Ancient Science of Life” Eclipta alba extract reduces ulcers and protects the stomach in rats.
6 citations
,
September 2015 in “Journal of Medicinal Chemistry” The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.
March 2021 in “Research Square (Research Square)” Ketoconazole's structure and dynamics are linked, aiding antifungal drug development.
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.